ReviewInnere Medizin (Heidelberg, Germany)2025
[Adherence, single pill and outcomes-What is confirmed and what does the reality look like?]
Review in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hypertension or dyslipidemia and patients in cardiovascular secondary protection usually require more pharmaceuticals to achieve the target values. For some years, a combination treatment with a single pill has been recommended for arterial hypertension and for most patients even from the beginning of treatment. OBJECTIVE AND
methodsThe aim of this review article is to present the current recommendations and illuminate the evidence with respect to cardiovascular outcomes for single pill treatment in comparison to loose combinations.
resultsThe achievement of the target values in arterial hypertension, dyslipidemia and in secondary prevention is insufficient. Poor adherence plays a major role in this. This greatly depends on the number of pills, a simple treatment schedule and as few treatment changes as possible. For this reason, national and international scientific societies recommend an initial combination treatment when possible in a single pill. This concept is supported by a broad evidence base for an improved adherence. There are now also investigations that show significant reductions in cardiovascular outcomes, including the overall mortality, for single pill treatment in comparison to the use of the same substances in identical doses in the form of loose combinations. Simultaneously, the use of a single pill leads to a reduction of the total treatment costs due to improved adherence, a lower number of hospitalizations and a reduction of cardiovascular outcomes. The implementation of the recommended concept is insufficient as combinations are still used for the majority of patients, contrary to the guidelines and despite the availability of single pills with the selected substances and doses.
conclusionThe use of single pills in cardiovascular treatment improves the adherence, reduces cardiovascular outcomes and is widely recommended by specialist societies. The improvement of the insufficient implementation in the clinical practice needs comprehensive efforts.
Indexed as
Identifiers
40856803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.